Press Releases

May 30, 2023

Acticor Biotech: progress in discussions with EU and US Regulatory Agencies

Press Releases

May 30, 2023

Acticor Biotech: progress in discussions with EU and US Regulatory Agencies

Press Releases

May 30, 2023

Acticor Biotech: progress in discussions with EU and US Regulatory Agencies

Press Releases

May 30, 2023

Acticor Biotech: progress in discussions with EU and US Regulatory Agencies

Press Releases

May 30, 2023

Acticor Biotech: progress in discussions with EU and US Regulatory Agencies

Press Releases

May 30, 2023

Acticor Biotech: progress in discussions with EU and US Regulatory Agencies

Press Releases

May 26, 2023

Participation of Acticor Biotech in ESOC 2023, first European Forum for Stroke Research

Press Releases

May 26, 2023

Participation of Acticor Biotech in ESOC 2023, first European Forum for Stroke Research

Press Releases

May 26, 2023

Participation of Acticor Biotech in ESOC 2023, first European Forum for Stroke Research

Press Releases

May 26, 2023

Participation of Acticor Biotech in ESOC 2023, first European Forum for Stroke Research

Press Releases

May 26, 2023

Participation of Acticor Biotech in ESOC 2023, first European Forum for Stroke Research

Press Releases

May 26, 2023

Participation of Acticor Biotech in ESOC 2023, first European Forum for Stroke Research

Press Releases

May 17, 2023

Report of the Combined General Meeting of May 12, 2023

Press Releases

May 17, 2023

Report of the Combined General Meeting of May 12, 2023

Press Releases

May 17, 2023

Report of the Combined General Meeting of May 12, 2023

Press Releases

May 17, 2023

Report of the Combined General Meeting of May 12, 2023

Press Releases

May 17, 2023

Report of the Combined General Meeting of May 12, 2023

Press Releases

May 17, 2023

Report of the Combined General Meeting of May 12, 2023

Press Releases

April 26, 2023

Availability of the 2022 Universal Registration Document and the preparatory documents for the combined general meeting of May 12, 2023

Press Releases

April 26, 2023

Availability of the 2022 Universal Registration Document and the preparatory documents for the combined general meeting of May 12, 2023

Press Releases

April 26, 2023

Availability of the 2022 Universal Registration Document and the preparatory documents for the combined general meeting of May 12, 2023

Press Releases

April 26, 2023

Availability of the 2022 Universal Registration Document and the preparatory documents for the combined general meeting of May 12, 2023

Press Releases

April 26, 2023

Availability of the 2022 Universal Registration Document and the preparatory documents for the combined general meeting of May 12, 2023

Press Releases

April 26, 2023

Availability of the 2022 Universal Registration Document and the preparatory documents for the combined general meeting of May 12, 2023

Press Releases

March 23, 2023

Acticor Biotech publishes its 2022 annual results and provides an update on its clinical progress

Press Releases

March 23, 2023

Acticor Biotech publishes its 2022 annual results and provides an update on its clinical progress

Press Releases

March 23, 2023

Acticor Biotech publishes its 2022 annual results and provides an update on its clinical progress

Press Releases

March 23, 2023

Acticor Biotech publishes its 2022 annual results and provides an update on its clinical progress

Press Releases

March 23, 2023

Acticor Biotech publishes its 2022 annual results and provides an update on its clinical progress

Press Releases

March 23, 2023

Acticor Biotech publishes its 2022 annual results and provides an update on its clinical progress

Press Releases

March 9, 2023

Acticor Biotech successfully completes a capital increase for a total gross amount of 12.2 million euros, via the issuance of 1,793,005 shares

Press Releases

March 9, 2023

Acticor Biotech successfully completes a capital increase for a total gross amount of 12.2 million euros, via the issuance of 1,793,005 shares

Press Releases

March 9, 2023

Acticor Biotech successfully completes a capital increase for a total gross amount of 12.2 million euros, via the issuance of 1,793,005 shares

Press Releases

March 9, 2023

Acticor Biotech successfully completes a capital increase for a total gross amount of 12.2 million euros, via the issuance of 1,793,005 shares

Press Releases

March 9, 2023

Acticor Biotech successfully completes a capital increase for a total gross amount of 12.2 million euros, via the issuance of 1,793,005 shares

Press Releases

March 9, 2023

Acticor Biotech successfully completes a capital increase for a total gross amount of 12.2 million euros, via the issuance of 1,793,005 shares

Press Releases

March 8, 2023

Acticor Biotech launches a capital increase for an amount of c. 10 million euros

Press Releases

March 8, 2023

Acticor Biotech launches a capital increase for an amount of c. 10 million euros

Press Releases

March 8, 2023

Acticor Biotech launches a capital increase for an amount of c. 10 million euros

Press Releases

March 8, 2023

Acticor Biotech launches a capital increase for an amount of c. 10 million euros

Press Releases

March 8, 2023

Acticor Biotech launches a capital increase for an amount of c. 10 million euros

Press Releases

March 8, 2023

Acticor Biotech launches a capital increase for an amount of c. 10 million euros

Press Releases

February 6, 2023

Acticor Biotech announces the appointment of Patricia Zilliox to the Board of Directors as an independent director

Press Releases

February 6, 2023

Acticor Biotech announces the appointment of Patricia Zilliox to the Board of Directors as an independent director

Press Releases

February 6, 2023

Acticor Biotech announces the appointment of Patricia Zilliox to the Board of Directors as an independent director

Press Releases

February 6, 2023

Acticor Biotech announces the appointment of Patricia Zilliox to the Board of Directors as an independent director

Press Releases

February 6, 2023

Acticor Biotech announces the appointment of Patricia Zilliox to the Board of Directors as an independent director

Press Releases

February 6, 2023

Acticor Biotech announces the appointment of Patricia Zilliox to the Board of Directors as an independent director

Press Releases

January 9, 2023

Update on Acticor Biotech's clinical developments with glenzocimab in the treatment of cardiovascular emergencies

Press Releases

January 9, 2023

Update on Acticor Biotech's clinical developments with glenzocimab in the treatment of cardiovascular emergencies

Press Releases

January 9, 2023

Update on Acticor Biotech's clinical developments with glenzocimab in the treatment of cardiovascular emergencies

Press Releases

January 9, 2023

Update on Acticor Biotech's clinical developments with glenzocimab in the treatment of cardiovascular emergencies

Press Releases

January 9, 2023

Update on Acticor Biotech's clinical developments with glenzocimab in the treatment of cardiovascular emergencies

Press Releases

January 9, 2023

Update on Acticor Biotech's clinical developments with glenzocimab in the treatment of cardiovascular emergencies

Press Releases

December 23, 2022

Acticor Biotech provides an update on the US regulatory discussion with the FDA

Press Releases

December 23, 2022

Acticor Biotech provides an update on the US regulatory discussion with the FDA

Press Releases

December 23, 2022

Acticor Biotech provides an update on the US regulatory discussion with the FDA

Press Releases

December 23, 2022

Acticor Biotech provides an update on the US regulatory discussion with the FDA

Press Releases

December 23, 2022

Acticor Biotech provides an update on the US regulatory discussion with the FDA

Press Releases

December 23, 2022

Press Releases

Acticor Biotech: progress in discussions with EU and US Regulatory Agencies

Acticor Biotech: progress in discussions with EU and US Regulatory Agencies

Acticor Biotech: progress in discussions with EU and US Regulatory Agencies

Acticor Biotech: progress in discussions with EU and US Regulatory Agencies

Acticor Biotech: progress in discussions with EU and US Regulatory Agencies

Acticor Biotech: progress in discussions with EU and US Regulatory Agencies

Participation of Acticor Biotech in ESOC 2023, first European Forum for Stroke Research

Participation of Acticor Biotech in ESOC 2023, first European Forum for Stroke Research

Participation of Acticor Biotech in ESOC 2023, first European Forum for Stroke Research

Participation of Acticor Biotech in ESOC 2023, first European Forum for Stroke Research

Participation of Acticor Biotech in ESOC 2023, first European Forum for Stroke Research

Participation of Acticor Biotech in ESOC 2023, first European Forum for Stroke Research

Report of the Combined General Meeting of May 12, 2023

Report of the Combined General Meeting of May 12, 2023

Report of the Combined General Meeting of May 12, 2023

Report of the Combined General Meeting of May 12, 2023

Report of the Combined General Meeting of May 12, 2023

Report of the Combined General Meeting of May 12, 2023

Availability of the 2022 Universal Registration Document and the preparatory documents for the combined general meeting of May 12, 2023

Availability of the 2022 Universal Registration Document and the preparatory documents for the combined general meeting of May 12, 2023

Availability of the 2022 Universal Registration Document and the preparatory documents for the combined general meeting of May 12, 2023

Availability of the 2022 Universal Registration Document and the preparatory documents for the combined general meeting of May 12, 2023

Availability of the 2022 Universal Registration Document and the preparatory documents for the combined general meeting of May 12, 2023

Availability of the 2022 Universal Registration Document and the preparatory documents for the combined general meeting of May 12, 2023

Acticor Biotech publishes its 2022 annual results and provides an update on its clinical progress

Acticor Biotech publishes its 2022 annual results and provides an update on its clinical progress

Acticor Biotech publishes its 2022 annual results and provides an update on its clinical progress

Acticor Biotech publishes its 2022 annual results and provides an update on its clinical progress

Acticor Biotech publishes its 2022 annual results and provides an update on its clinical progress

Acticor Biotech publishes its 2022 annual results and provides an update on its clinical progress

Acticor Biotech successfully completes a capital increase for a total gross amount of 12.2 million euros, via the issuance of 1,793,005 shares

Acticor Biotech successfully completes a capital increase for a total gross amount of 12.2 million euros, via the issuance of 1,793,005 shares

Acticor Biotech successfully completes a capital increase for a total gross amount of 12.2 million euros, via the issuance of 1,793,005 shares

Acticor Biotech successfully completes a capital increase for a total gross amount of 12.2 million euros, via the issuance of 1,793,005 shares

Acticor Biotech successfully completes a capital increase for a total gross amount of 12.2 million euros, via the issuance of 1,793,005 shares

Acticor Biotech successfully completes a capital increase for a total gross amount of 12.2 million euros, via the issuance of 1,793,005 shares

Acticor Biotech launches a capital increase for an amount of c. 10 million euros

Acticor Biotech launches a capital increase for an amount of c. 10 million euros

Acticor Biotech launches a capital increase for an amount of c. 10 million euros

Acticor Biotech launches a capital increase for an amount of c. 10 million euros

Acticor Biotech launches a capital increase for an amount of c. 10 million euros

Acticor Biotech launches a capital increase for an amount of c. 10 million euros

Acticor Biotech announces the appointment of Patricia Zilliox to the Board of Directors as an independent director

Acticor Biotech announces the appointment of Patricia Zilliox to the Board of Directors as an independent director

Acticor Biotech announces the appointment of Patricia Zilliox to the Board of Directors as an independent director

Acticor Biotech announces the appointment of Patricia Zilliox to the Board of Directors as an independent director

Acticor Biotech announces the appointment of Patricia Zilliox to the Board of Directors as an independent director

Acticor Biotech announces the appointment of Patricia Zilliox to the Board of Directors as an independent director

Update on Acticor Biotech's clinical developments with glenzocimab in the treatment of cardiovascular emergencies

Update on Acticor Biotech's clinical developments with glenzocimab in the treatment of cardiovascular emergencies

Update on Acticor Biotech's clinical developments with glenzocimab in the treatment of cardiovascular emergencies

Update on Acticor Biotech's clinical developments with glenzocimab in the treatment of cardiovascular emergencies

Update on Acticor Biotech's clinical developments with glenzocimab in the treatment of cardiovascular emergencies

Update on Acticor Biotech's clinical developments with glenzocimab in the treatment of cardiovascular emergencies

Acticor Biotech provides an update on the US regulatory discussion with the FDA

Acticor Biotech provides an update on the US regulatory discussion with the FDA

Acticor Biotech provides an update on the US regulatory discussion with the FDA

Acticor Biotech provides an update on the US regulatory discussion with the FDA

Acticor Biotech provides an update on the US regulatory discussion with the FDA

Acticor Biotech provides an update on the US regulatory discussion with the FDA

Subscribe to email alert

Navigation

Contact Us